A Phase I/II Open Label Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of ALXN6000 In Patients With Relapsing Or Refractory B-Cell Chronic Lymphocytic Leukemia Or Multiple Myeloma

Inclusion Criteria:

- Relapsing or Refractory B CLL or MM

- ECOG performance status 0-2

- Anticipated survival of greater than 6 months.

- Female patients of childbearing potential must agree to use two forms of
contraception

- Patients must have a standard indication for treatment of their malignancy

- Is willing and able to give written informed consent.

Exclusion Criteria:

- Absolute neutrophil count (ANC) < 1000 x 109/L

- Platelet count < 50,000 x 109/L

- Pregnant or lactating women.

- Prior history of autoimmune hemolysis requiring therapy.

- Prior history of immune thrombocytopenia.

- Active autoimmune disease requiring immunosuppressive therapy.

- Positive Coombs' Test (neither Direct or Indirect)

- Ongoing corticosteroid treatment equivalent to the mineralocortacoid potency of 10
milligram (mg) /day of prednisone, or greater, for any condition.

- Prior stem cell transplantation within 4 weeks prior to enrollment.

- Prior chemotherapy for the applicable malignancy within 30 days of enrollment.

- Neurosurgery or cranial radiation therapy within one year of enrollment.

- Clinically significant renal, hepatic or heart disease.